A high performance liquid chromatographic method with UV detection was developed and validated for simultaneous determination of Pioglitazone and Clopidogrel. Separation was performed on a C18 column by isocratic elution with a mobile phase of Methanol: Acetonitrile : Water (80:10:10) at pH 4.6. The UV detection was set at 230 nm. The method proved to be specific, accurate, precise and linear over the concentration ranges of 20-120ppm for both Pioglitazone and Clopidogrel with correlation coefficients always >0.999 for both drugs. The intra-day and inter-day precision and accuracy were less than 2 for both analytes.
INTRODUCTION
Clopidogrel is an oral, thienopyridine class antiplatelet agent used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease. It is marketed by Bristol-Myers Squibb and Sanofi under the trade name Plavix. The drug works by irreversibly inhibiting a receptor called P2Y 12 , an adenosine diphosphate (ADP) chemoreceptor on platelet cell membranes (1) . Adverse effects include hemorrhage, severe neutropenia, and thrombotic thrombocytopenic purpura (TTP). Clopidogrel is a prodrug, the action of which may be related to an ADP receptor on platelet cell membranes.
Figure 1: Structure of Clopidogrel
Clopidogrel is indicated for [2] Prevention of vascular ischemic events in patients with symptomatic atherosclerosis, Acute coronary syndrome without ST-segment elevation (NSTEMI), ST elevation MI (STEMI). Platelet inhibition can be demonstrated two hours after a single dose of oral clopidogrel, but the onset of action is slow, so that a loading-dose of 300 mg is usually administered.
Serious adverse drug reactions associated with clopidogrel therapy includes, Severe neutropenia, Thrombotic thrombocytopenic purpura (TTP) [3] Hemorrhage -The annual incidence of hemorrhage may be increased by the co-administration of aspirin. [4] , Gastrointestinal Hemorrhage, Cerebral Hemorrhage (Incidence: 0.1 to 0.4% annually). Use of non-steroidal anti-inflammatory drugs is discouraged in those taking clopidogrel due to increased risk of digestive tract hemorrhage.
Pioglitazone is a prescription drug of the class thiazolidinedione (TZD) with hypoglycemic (antihyperglycemic, antidiabetic) action to treat diabetes. Pioglitazone is marketed as trademarks Actos in the USA, Canada, the UK and Germany, Glustin in Europe,"Glizone" and "Pioz" in India by Zydus Cadila and USV Limited respectively and Zactos in Mexico by Takeda Pharmaceuticals [5] .Its cardiovascular safety profile compares favorably with rosiglitazone (Avandia), which was withdrawn after concerns about an increased risk of cardiac events. However, pioglitazone has subsequently been found to be associated with bladder tumors and has been withdrawn in some countries.
Figure 2: Structure of Pioglitazone
Pioglitazone is used for the treatment of diabetes mellitus type 2 (previously known as noninsulin-dependent diabetes mellitus, NIDDM) in monotherapy and in combination with asulfonylurea, metformin, or insulin. Pioglitazone has also been used to treat non-alcoholic steatohepatitis (fatty liver), but this use is presently considered experimental. [6] Pioglitazone has also been found to reduce the risk of conversion from prediabetes to diabetes mellitus type 2 by 72%. [7] Pioglitazone can cause fluid retention and peripheral edema. As a result, it may precipitate congestive heart failure (which worsens with fluid overload in those at risk). It may cause anemia. Mild weight gain is common due to increase in subcutaneous adipose tissue. In studies, patients on pioglitazone had an increased proportion of upper respiratory tract infection, sinusitis, headache, myalgia and tooth problems. The risk of hypoglycemia is low in the absence of other drugs that lower blood glucose.
MATERIALS AND METHODS

Chemicals and reagents
Reagents used like Acetonitrile, Methanol, Water which are of HPLC grade were purchased from E.Merck, Mumbai, India
Instrumentation and analytical conditions
The analysis of the drug was carried out on Shimadzu HPLC model (VP series) containing LC-10AT (VP series) pump, variable wave length programmable UV/visible detector SPD-10AVP and rheodyne injector (7725i) with 20µl fixed loop. Chromatographic analysis was performed using Inertsil ODS C-18 column with 250 x 4.6mm internal diameter and 5µm particle size. Shimadzu electronic balance (AX-200) was used for weighing. Isocratic elution with Acetonitrile: Methanol 10:90 (V/V) was selected with a flow rate of 1.0 ml min -.The detection wavelength was set at 235 nm with a runtime of 10 min. The mobile phase was prepared freshly and it was degassed by sonicating for 5 min before use. The column was equilibrated for at least 30min with the mobile phase flowing through the system. The column and the HPLC system were kept at ambient temperature.
Preparation of Stock, working standard solutions and Sample solutions
Standard solutions of concentration 1000 µg/mL of Pioglitazone and 1000 µg/mL of Clopidogrel were prepared separately using methanol. From standard solutions further solution are prepared by using methanol.
The formulation tablets of Pioglitazone (ACTOS -45mg) and Clopidogrel (Plavix -75mg) were crushed to give finely powdered material. Powder equivalent to 10 mg of drug was taken separately in 10 ml of volumetric flask containing 5 ml of Methanol and was shaken to dissolve the drug and then filtered through Ultipor N 66 Nylon 6,6 membrane sample filter paper. Volume of the filtrate was adjusted to the mark with the same solvent to obtain concentration of 80 ppm. 1ml from the each of the two drug solutions were taken and mixed well and injected into HPLC system and the resultant assay was calculated based on the peak areas.
Optimization of HPLC Method
All drugs were subjected to chromatographic analysis using mobile phases of differing pH, flow rate using the under mentioned chromatographic conditions. The changes in the retention time of all drugs were noted as a function of changing mobile phase, pH, flow rate, strength and selectivity. Initially methanol: water in the ratio of (80: 20) was tried but both the peaks merged. Later methanol: water: Acetonitrile in the ratio of (80: 10:10) was tried and it was found that both the peaks were well separated with acceptable resolution. Hence methanol: water: Acetonitrile in the ratio of (80: 10:10) at flow rate of 1.2 mL/min was finalized which gave acceptable retention time, plates and good resolution for Pioglitazone and Clopidogrel ( Figure: 3)
Validation of the method
Validation of the optimized HPLC method was carried out with respect to the following parameters.
LOD and 10 for LOQ, respectively. To determine the LOD and LOQ, serial dilutions of mixed standard solution of Pioglitazone and Clopidogrel was made from the standard stock solution. The samples were injected in LC system and measured signal from the samples was compared with those of blank samples.
Robustness of the method:
To evaluate robustness of a HPLC method, few parameters were deliberately varied. The parameters included variation of flow rate, percentage of mobile phase and wavelength. Robustness of the method was done at three different concentration level 80 µg/mL for Pioglitazone and Clopidogrel.
Specificity:
The specificity of the method towards the drug was established through study of resolution factor of the drug peak from the nearest resolving peak. The peak purity of Pioglitazone and Clopidogrel was determined by comparing the spectrum at three different regions of the spot i.e. peak start (S), peak apex (M) and peak end (E). Effect of excipients of formulation was studied for whether it interfered with the assay.
Accuracy: Accuracy of the method was carried out by applying the method to drug sample to which know amount of Pioglitazone and Clopidogrel standard powder corresponding to 50, 100 and 150 % of label claim had been added (Standard addition method), mixed and the powder was extracted and analyzed by running chromatogram in optimized mobile phase. 
H.P.L.C CONDITIONS Result
ELUTION
Table3: Interday Precision results
LOD and LOQ:
Signal-to-noise ratios of 3:1 and 10:1 were obtained for the LOD and LOQ respectively. The LOD and LOQ were found to be 0.25µg/mL and 0.825 µg/mL for Pioglitazone and 0.1 µg/mL and 0.33 µg/mL for Clopidogrel, respectively.
Robustness of the method:
Each factor selected (except columns from different manufacturers) was changed at three levels (−0.1, 0 and 0.1). One factor at the time was changed to estimate the effect. Thus, Robustness was performed under small changes of three chromatographic parameters (factors). Insignificant differences in peak areas were observed (Table 4) . Recovery: As shown from the data in Table 3 
Parameter
CONCLUSION
HPLC method was developed and validated as per ICH guidelines. UV detection allowed an accurate quantitation of chromophoric compounds. The drug was analyzed by HPLC method using Chromosil C18, 250 ×4.6 mm with isocratic conditions and simple mobile phase containing MEOH 80%, ACN 10%, Water 10 % at flow rate of 1.2 mL/min using UV detection at 230 nm. The procedure has been evaluated for the linearity, accuracy, precision and robustness in order to ascertain the suitability of the analytical method. The method was also applied to marketed samples. It has been proved that the method is selective and linear between concentration range 20-120 µg/mL for both Pioglitazone and Clopidogrel. The LOD and LOQ were found to be 0.25µg/mL and 0.825 µg/mL for Pioglitazone and 0.1 µg/mL and 0.33 µg/mL for Clopidogrel, respectively. Statistical analysis proves that the method is suitable for the analysis of Pioglitazoneand Clopidogrelas bulk drug and in pharmaceutical formulation without any interference from the excipients. It may be extended to study the degradation kinetics of Pioglitazone and Clopidogrel and also for its estimation in plasma and other biological fluids.
